Page last updated: 2024-12-06

loxtidine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

loxtidine: structure given in first source; RN given refers to parenet cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

loxtidine : A triazole that consists of 1,2,4-triazole bearing a methyl substituent at position 1, a hydroxymethyl substituent at position 3 and a {3-[3-(piperidin-1-ylmethyl)phenoxy]propyl}amino group at position 5. A highly potent and selective H2-receptor antagonist. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID55473
CHEMBL ID2110857
CHEBI ID6550
SCHEMBL ID1142
MeSH IDM0119338

Synonyms (36)

Synonym
{1-methyl-5-[(3-{[3-(piperidin-1-ylmethyl)phenyl]oxy}propyl)amino]-1h-1,2,4-triazol-3-yl}methanol
lavoltidine
76956-02-0
loxtidine
lavoltidinum [inn-latin]
loxtidina [spanish]
ah 23844
lavoltidina [inn-spanish]
lavoltidine [inn:ban]
1h-1,2,4-triazole-3-methanol, 1-methyl-5-((3-(3-(1-piperidinylmethyl)phenoxy)propyl)amino)-
loxtidinum [latin]
[1-methyl-5-[3-[3-(piperidin-1-ylmethyl)phenoxy]propylamino]-1,2,4-triazol-3-yl]methanol
lavoltidina
x16k5179v5 ,
unii-x16k5179v5
lavoltidinum
loxtidina
loxtidinum
CHEBI:6550 ,
[1-methyl-5-({3-[3-(piperidin-1-ylmethyl)phenoxy]propyl}amino)-1h-1,2,4-triazol-3-yl]methanol
SCHEMBL1142
ah-23844 free base
1-methyl-5-((3-((.alpha.-piperidino-m-tolyl)oxy)propyl)amino)-1h-1,2,4-triazole-3-methanol
loxotidine
lavoltidine [inn]
lavoltidine [who-dd]
1-methyl-5-[[3-[3-(1-piperidinylmethyl)phenoxy]propyl]amino]-1h-1,2,4-triazole-3-methanol
VTLNPNNUIJHJQB-UHFFFAOYSA-N
CHEMBL2110857
DTXSID0020785
DB12884
Q6694396
loxtidine;ah-234844
HY-121450
CS-0082069
AKOS040741942

Research Excerpts

Treatment

ExcerptReferenceRelevance
"Loxtidine treatment, with or without YF476, induced a mild shift in T-helper cell polarization."( Synergistic inhibitory effects of gastrin and histamine receptor antagonists on Helicobacter-induced gastric cancer.
Carlson, JE; Cui, G; Dockray, GJ; Fox, JG; Frederick, DM; Ge, Z; Houghton, J; Rogers, AB; Takaishi, S; Varro, A; Wang, TC; Whary, MT, 2005
)
1.05

Dosage Studied

ExcerptRelevanceReference
" Hourly dosing with hydrochloric acid reversed the protective effect of ranitidine, cimetidine and loxtidine on macroscopic damage and, histologically, this was associated with the widespread appearance of antral ulcers and a reduction in the proportion of mucosal damage caused by superficial erosions."( The role of acid in the pathogenesis of indomethacin-induced gastric antral ulcers in the rat.
Clayton, NM; Oakley, I; Trevethick, MA; Williams, LV, 1996
)
0.51
") dosing in rats, six of eight drugs produced dose- and time-related antinociception on both the tail flick and hot plate tests over a nearly eight-fold range of potencies."( Antinociceptive, brain-penetrating derivatives related to improgan, a non-opioid analgesic.
Hough, LB; Lu, Q; Montero, MJ; Nalwalk, JW; Shan, Z; Svokos, K; Wentland, MP, 2005
)
0.33
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
H2-receptor antagonistH2-receptor antagonists are the drugs that selectively bind to but do not activate histamine H2 receptors, thereby blocking the actions of endogenous histamine.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
triazolesAn azole in which the five-membered heterocyclic aromatic skeleton contains three N atoms and two C atoms.
piperidines
aromatic etherAny ether in which the oxygen is attached to at least one aryl substituent.
primary alcoholA primary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has either three hydrogen atoms attached to it or only one other carbon atom and two hydrogen atoms attached to it.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (45)

TimeframeStudies, This Drug (%)All Drugs %
pre-199013 (28.89)18.7374
1990's27 (60.00)18.2507
2000's3 (6.67)29.6817
2010's2 (4.44)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 18.24

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index18.24 (24.57)
Research Supply Index3.85 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (18.24)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews4 (8.70%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other42 (91.30%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Randomized, Double-blind, Four Period Cross-over Comparison of the Effect of Two Doses Lavoltidine, Esomeprazole, and Placebo on 24 Hour Gastric pH and Frequency of Heartburn in Symptomatic GERD Subjects Without Esophageal Erosions [NCT00405119]Phase 292 participants (Actual)Interventional2006-05-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]